Lymphoma is one of the most commonly encountered cancers in the dog. The incidence of canine lymphoma has steadily increased with approximately 84 per 10,000 dogs diagnosed each year. This randomized, double-masked, placebo-controlled, GCP pivotal field study is evaluating the effectiveness and safety of verdinexor for the treatment of naïve or first relapse stages II, III and IV lymphoma in client owned dogs. Diagnosis of lymphoma must be confirmed by cytology or biopsy for the dog to be eligible for this study. Dogs will be randomized to receive the investigational veterinary product or a placebo treatment (tablets) to be administered with food twice weekly at least 72 hours apart for 8 weeks. After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits. Owners will be required to report and record abnormal daily observations and dosing using a phone app at home throughout the study.
No preventative measures are currently available but it is recommended that breeds at a higher risk of developing lymphoma being screened by their veterinarian on a regular basis in an attempt to identify the disease at the earliest stage possible.
The most effective therapy for most types of canine lymphoma is chemotherapy. In some cases, surgery or radiation therapy may also be recommended. There are numerous chemotherapy treatment protocols for dogs with multicentric lymphoma. As discussed below, most dogs with lymphoma experience remission of their cancer following treatment, and side effects are usually not severe. Currently, the protocols that achieve the highest rates of remission and longest overall survival times involve combinations of drugs given over several weeks to months. The median length of survival of dogs with multicentric lymphoma treated with UW-25 chemotherapy is between 9-13 months. (The term “median” implies that 50% of dogs will survive beyond this time point and 50% of treated dogs will die before this time point.) Various other factors, such the type of lymphoma your dog has or its stage of disease, may affect your dog’s overall prognosis.
You may be eligible to receive a $1,000 credit applied to your account at the clinical study site, additionally funding for the study includes:
Initial Study Screening
Scheduled Study Lab Work
Recheck visits and Exams
Managment of side effects
If your dog enrolls in the study and you are able to comply with all study requirements, a $1,000 credit will be applied to your account at the clinical study site to be used towards further medical care once your dog is off the study.
Additionally this study is fully funded. Funding includes the initial study screening, the study treatment and administration, scheduled study lab work, recheck visits and exams, and management of side effects that are thought to be directly related to participation in the study.
Day 0: In-hospital treatment
Bi-weekly evaluation visits at study site
After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits.
1. VCA Animal Diagnostic Clinic
4444 Trinity Mills Rd, Dallas, TX 75287
2. Manley Animal Hospital
3812 SE Adams Rd, Bartlesville, OK 74006
3. East Lincoln Animal Hospital
7555 NC 73 Hwy, Denver, NC 28037
4. MedVet Akron
1321 Centerview Cir, Akron, OH 44321
5. MedVet Salt Lake City
331 W Bearcat Dr, South Salt Lake, UT 84115
6. Franklin Animal Clinic
2990 N Morton St, Franklin, IN 46131
7. University of Wisconsin-Madison School of Veterinary Medicine
2015 Linden Dr, Madison, WI 53706
8. Cummings School of Veterinary Medicine Tufts University
200 Westboro Rd, North Grafton, MA 01536
9. PVSEC North Hills
807 Camp Horne Rd, Pittsburgh, PA 15237
10. University of Georgia
2200 College Station Rd, Athens, GA 30605
11. Metropolitan Veterinary Hospital - Cleveland East
734 Alpha Dr, Highland Heights, OH 44143
Chief Medical Officer, DVM, DACVIM
Dr. David Bruyette received his Doctor of Veterinary Medicine degree from the University of Missouri. Subsequently, he completed an internship at Purdue University and residency in internal medicine at the University of California-Davis. He was a staff internist at the West Los Angeles Veterinary Medical Group and a member of the Department of Comparative Medicine at Stanford University. Dr. Bruyette was an Assistant Professor and Head of Internal Medicine at Kansas State University and Director of the Analytical Chemistry Laboratory at Kansas State. He was most recently, Medical Director of the VCA West Los Angeles Animal Hospital, one of the largest 24-hour emergency/specialty practices in the country. Dr. Bruyette is a diplomate of the American College of Veterinary Internal Medicine and a member of the Endocrine Society.